Ingo Kleiter, Germany

Marianne-Strauß-Klinik Germany
Name, first name Prof. Kleiter, Ingo
Date/Place of Birth: 29.10.1972 / Erlangen, Germany
Affiliations: 1 Marianne-Strauß-Klinik,
Behandlungszentrum Kempfenhausen für Multiple Sklerose Kranke,
Milchberg 21, 82335 Berg, Germany

2 Ruhr-University Bochum, 44791 Bochum, Germany

Present Position: Medical Director
Professional qualifications Date Place
Doctor´s thesis (“Dr. med.”) 2000 University of Erlangen-Nürnberg, Germany
Medical license acquired (“Approbation”) 2001 Würzburg, Germany
Board certification Neurology 2007 München, Germany
Assistant Professor for Clinical and Experimental Neuroimmunology 2011 Ruhr-University Bochum, Germany
Associate Professor 2018 Ruhr-University Bochum, Germany
Education/professional experience From To Place
Medical School 1992 1999 University of Erlangen-Nürnberg, Germany
Resident 2000 2003 Department of Neurology, University of Regensburg, Germany
Research fellow 2003 2004 Institute of Genetics, University of Cologne, Germany
Resident, since 2007 attending 2004 2011 Department of Neurology, University of Regensburg, Germany
Attending (consultant) 2011 2017 Department of Neurology, Ruhr-University Bochum, Germany
Medical Director 2017 Ongoing Marianne-Strauß-Klinik, Germany
Membership of medical scientific societies / consortia Since  
  2003 Deutsche Gesellschaft für Neurologie (DGN), Germany
2008 Deutsche Gesellschaft für Klinische Neurophysiologie (DGKN), Germany Certificates: EMG, EP, Ultrasound
2009 Neuromyelitis optica study group (NEMOS), Germany
  2013 International Clinical Consortium, Guthy Jackson Foundation, Los Angeles, USA

 

Selected publications

Yamamura T, Kleiter I, Fujihara  K, Palace  J, Greenberg  B, Zakrzewska-Pniewska B, Patti F, Tsai CP, Saiz A, Yamazaki H, Kawata Y, Wright P, De Seze J. Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder. NEJM 2019 Nov 28;381(22):2114-2124.

Kleiter I, Gahlen A, Borisow N, …, NEMOS (Neuromyelitis Optica Study Group). Apheresis therapies for NMOSD attacks: a retrospective study of 207 therapeutic interventions. Neurol Neuroimmunol Neuroinflamm 2018 Sep 26;5(6):e504.

Kleiter I, Gahlen A, Borisow N, …, NEMOS (Neuromyelitis Optica Study Group). Therapy of neuromyelitis optica exacerbations:
a retrospective evaluation of 871 attacks and 1153 treatment courses. Ann Neurol 2016; 79: 206-216.

Stellmann J, Krumbholz M, Friede T, …, Kleiter I. Immunotherapies in neuromyelitis optica spectrum disorder: Efficacy and predictors of response. J Neurol Neurosurg Psychiatry 2017;88(8):639-647

Ringelstein M, Ayzenberg I, Harmel J, Lauenstein AS, Lensch E, Stogbauer F, Hellwig K, Ellrichmann G, Stettner M, Chan A, Hartung HP, Kieseier B, Gold R, Aktas O, Kleiter I. Long-term Therapy With Interleukin 6 Receptor Blockade in Highly Active Neuromyelitis Optica Spectrum Disorder. JAMA Neurol. 2015; 72: 756-63.

 

 

Berg, 20. Jan 2020